American Pharma Mfg. Inc. — FDA Warning Letter, 2026-08-04: CGMP/Dietary Supplement/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded
TL;DR
The FDA issued a warning letter to American Pharma Mfg. Inc. (Ontario, CA) on August 4, 2026 (CMS #728227) following a March 16-27, 2026 inspection, citing significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR Part 111 that render dietary supplements manufactured at the facility adulterated. Violations include unqualified quality control personnel, inadequate facility sanitation (powder buildup on equipment, holes and temporary patches in walls, pest entry gaps, unsanitary wastewater storage), improper storage of cleaning compounds near production areas, and failure to establish component specifications; the company's April 2026 responses were deemed insufficient to demonstrate adequate corrective action.
Argus analysis
# FDA Warning Letter Analysis: American Pharma Mfg. Inc.
**Facility Overview and Violations**
The FDA's Human Foods Program issued a warning letter to American Pharma Mfg. Inc., located in Ontario, California, following an inspection conducted March 16–27, 2026. The agency identified significant violations of Current Good Manufacturing Practice (CGMP) requirements for dietary supplements. The violations rendered the company's dietary supplement products adulterated under federal law because they were manufactured under conditions that failed to meet established safety and quality standards. The letter was addressed to Chief Operating Officer Vishal D. Savalia on August 4, 2026.
**Regulatory Citations and Their Meaning**
The warning cites 21 CFR Part 111, which establishes CGMP requirements specific to dietary supplement manufacturing. Key violations included: unqualified personnel performing quality control (21 CFR 111.12(b)); inadequate facility sanitation, pest control, and plumbing systems (21 CFR 111.15); missing component and finished product specifications (21 CFR 111.70); incomplete batch production records lacking yield data and real-time documentation (21 CFR 111.255 and 111.260); and inoperative metal detection controls (21 CFR 111.365(i)). These sections collectively establish mandatory controls over personnel competency, facility conditions, product specifications, manufacturing documentation, and contamination prevention.
**Response Timeline and Industry Observations**
American Pharma submitted responses on April 14 and 17, 2026, but the FDA deemed them inadequate—the company provided limited documentation and failed to demonstrate completed corrective actions. Compliance officers in the dietary supplement sector should monitor whether the company submits a satisfactory corrective action plan, as the warning letter signals FDA consideration of enforcement actions including product seizure or injunctive relief. The lack of documented evidence and persistent gaps in the company's responses suggest heightened regulatory scrutiny ahead.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER American Pharma Mfg. Inc. MARCS-CMS 728227 — August 04, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Dietary Supplements Recipient: Recipient Name Mr. Vishal D. Savalia Recipient Title Chief Operating Officer American Pharma Mfg. Inc. 1845 S. Vineyard Ave Ste 5 Ontario , CA 91761-7762 United States Issuing Office: Human Foods Program United States August 4, 2026 WARNING LETTER CMS #728227 Dear Mr. Savalia: The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1845 S. Vineyard Ave, Ste 5, Ontario, CA, from March 16-27, 2026. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. At the conclusion of the inspection on March 27, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 14 and 17, 2026, and we address your responses below. Adulterated Dietary Supplements The inspection of your facility from March 16-27, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Your significant violations of the CGMP requirements are as follows: 1. You failed to ensure that each person who is identified to perform quality control operations is qualified to do so, as required by 21 CFR 111.12(b). Specifically, neither your Operations Manager nor your Production Manager, who are performing the responsibilities of quality control, is qualified to do so, as neither is knowledgeable about the applicable requirements. We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you identified an employee to lead your quality control unit; however, you provided no information demonstrating that this person is qualified. 2. You failed to meet sanitation requirements that apply to your physical plant and grounds, as required by 21 CFR 111.15. Specifically, during the inspection, our investigator observed the following: You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). Specificall…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has American Pharma Mfg. Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for American Pharma Mfg. Inc. as of 2026-09-29. Argus ingests new FDA enforcement records daily.
- What FDA violations was American Pharma Mfg. Inc. cited for?
- The FDA Warning Letter to American Pharma Mfg. Inc. (issuing office: Human Foods Program) cites: CGMP/Dietary Supplement/Adulterated/Misbranded. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to American Pharma Mfg. Inc.?
- FDA issued the letter (MARCS-CMS 728227) on 2026-08-04 and posted it publicly on fda.gov on 2026-09-29.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). American Pharma Mfg. Inc. — FDA Warning Letter, 2026-08-04: CGMP/Dietary Supplement/Adulterated/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-american-pharma-mfg-inc-2026-08-04-cgmp
"American Pharma Mfg. Inc. — FDA Warning Letter, 2026-08-04: CGMP/Dietary Supplement/Adulterated/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-american-pharma-mfg-inc-2026-08-04-cgmp.
Argus HQ Research. "American Pharma Mfg. Inc. — FDA Warning Letter, 2026-08-04: CGMP/Dietary Supplement/Adulterated/Misbranded." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-american-pharma-mfg-inc-2026-08-04-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_american_pharma_mfg_inc_2026_08_04_cgmp_2026,
title = {American Pharma Mfg. Inc. — FDA Warning Letter, 2026-08-04: CGMP/Dietary Supplement/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-american-pharma-mfg-inc-2026-08-04-cgmp},
note = {Accessed: September 30, 2026}
}